L’European Medicines Agency (EMA) has recommended the marketing authorization of Abrysvoand Vaccine to protect the babies up to 6 months and over 60 from diseases of the lower respiratory tract caused by the respiratory syncytial virus (rsv). Now the word passes to European Commission: the final decision is expected in the coming weeks and will apply to all 27 EU Member States (includingItalia), plus Iceland, Liechtenstein and Norway.
Read Also Health | by FQ.
Syncytial virus, the experts: “Include monoclonal antibodies in childhood immunization”
The RSV is a respiratory virus common which usually causes mild symptoms, similar to those of a cold, but which can be serious in people vulnerable, including infants, the elderly and people with lung or heart disease and diabetes. The virus is one of main causes of hospitalization in patients pediatric patients, but at the same time represents a serious danger for the geriatric population. In Italy the number of hospitalized children in therapy intensive. The latest alarm in December 2022, when the experts of the Italian Society of Neonatology (Sin) had highlighted that RSV was causing “a high number of hospitalizations of newborns and children in the first and second year of life“. Also in autumn 2021 in Italy and in other countries an increase in pediatric hospitalizations had been recorded. TO November 2021 little Giuseppe had died in the Stabia hospital st leonard. And also Fedez e Clare Ferragni they had wanted to raise awareness on the subject after their daughter’s hospitalization.
Read Also Science | By 30science for The Fact.
“Accurate review of Pfizer syncytial virus vaccine data”, the appeal of some scientists
Abrysvo, the first anti-RSV vaccine to get the green light from the EMA agency, is bivalent and recombinant. “A significant step forward”, he defines it Annaliesa AndersonSenior Vice President e Chief Scientific Officer, Vaccine Research and Development di Pfizer. The opinion of the EMA, continues Anderson in a note from the American pharmaceutical company, “represents a significant step forward in our commitment to help prevent RSV disease in the elderly and newborns. If approved, our RSV vaccine candidate for donne in pregnancy would help protect newborns as early as birth and up to 6 months of age, when they are at higher risk of severe RSV disease and complications. This, together with approval in the elderly, would mark significant progress in terms of public health for the prevention of RSV disease throughout Europe”.
2023-07-21 15:42:19
#Syncytial #virus #RSV #EMA #recommends #green #light #vaccine #infants #60s #Fatto #Quotidiano
